I-MAB Filed 2023 Annual Report on Form 20-F

I-Mab, a global biotech company, filed its 2023 annual report on Form 20-F with the SEC.

Rhea-AI Summary

I-Mab, a global biotech company, filed its 2023 annual report on Form 20-F with the SEC. The report focuses on the development of immunotherapies for cancer treatment. It can be accessed on the company's investor relations website and the SEC's website. Shareholders and ADS holders can request hard copies free of charge.

Argus Session date unavailable

-1.67% session move Open Argus

Details

News Market Reaction – IMAB

The recorded move for IMAB in the trading session of this news was -1.67%.

Data tracked by StockTitan Argus. Session date unavailable.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

ROCKVILLE, Md., April 30, 2024 /PRNewswire/ -- I-Mab (the "Company") (NASDAQ: IMAB), a U.S.-based, global biotech company, exclusively focused on the development and potential commercialization of highly differentiated immunotherapies for the treatment of cancer, today announced that it has filed its annual report on Form 20-F for the year ended December 31, 2023 with the U.S. Securities and Exchange Commission ("SEC") on April 30, 2024.

The annual report is available on the Company's investor relations website at ir.i-mabbiopharma.com and on the SEC's website at www.sec.gov. The Company will provide hard copies of the annual report, free of charge, to its shareholders and ADS holders upon written request. Requests should be directed to Investor Relations, I-Mab, 2440 Research Blvd., Suite 400, Rockville, MD, 20850.

About I-Mab

I-Mab (NASDAQ: IMAB) is a U.S.-based global biotech company, exclusively focused on the development and potential commercialization of highly differentiated immunotherapies for the treatment of cancer. I-Mab has established operations in the U.S. in Rockville, Maryland, and in San Diego, California. For more information, please visit http://www.i-mabbiopharma.com and follow us on LinkedIn and X.

I-Mab Contacts

Investors & Media

Tyler Ehler

Senior Director, Investor Relations

IR@i-mabbiopharma.com

 

View original content to download multimedia:https://www.prnewswire.com/news-releases/i-mab-filed-2023-annual-report-on-form-20-f-302130508.html

SOURCE I-Mab Biopharma

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

Where can I access I-Mab's 2023 annual report?

I-Mab's 2023 annual report on Form 20-F can be accessed on the company's investor relations website and the SEC's website.

What is I-Mab's stock symbol?

I-Mab's stock symbol is IMAB.

How can shareholders and ADS holders request a hard copy of the annual report?

Shareholders and ADS holders can request hard copies of the annual report free of charge by contacting Investor Relations at I-Mab's address in Rockville, MD.